Abcon Therapeutics, Inc.

Cleveland, OH

UEI
YE2GVFPK6577
CAGE
8SZ24
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Subchapter S Corporation
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
10000 Cedar Ave, Cleveland, OH 44106, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of a novel antibody-drug conjugate for treating t-cell lymphoma. R41CA275639 National Cancer Institute (NIH) $1,208,040
Development of a new drug for treating autoimmune uveitis R41EY033243 National Eye Institute (NIH) $766,164

Quick answers

Is Abcon Therapeutics, Inc. registered in SAM.gov?

Yes. Abcon Therapeutics, Inc.'s SAM.gov registration is active through October 6, 2027.

What is Abcon Therapeutics, Inc.'s most recent federal award?

Abcon Therapeutics, Inc.'s most recent federal grant award is Development of a novel antibody-drug conjugate for treating t-cell lymphoma (R41CA275639), from National Cancer Institute (NIH), on September 19, 2022.

On GovTribe

See Abcon Therapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login